You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 19, 2025

Patent: 10,002,635


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,002,635
Title:Systems and methods for information capture
Abstract: Disclosed herein are information capture systems and related methods. An information capture system includes a sensor secured to an object configured to be involved with a possible event. The sensor is configured to detect one or more stimuli that are associated with the possible event, and transmit a sensor signal indicating data corresponding to the one or more stimuli. The information capture system also includes a recording device configured to record information responsive to a triggering event determined from the sensor signal. A method includes analyzing sensor data from the sensor, determining, from the sensor data, that a triggering event occurred, and recording post-trigger information following the determination of the triggering event.
Inventor(s): Mack; David Matthias (Cameron Park, CA), Dold; Brian Dempsey (Placerville, CA)
Assignee: SENWORTH, INC. (Cameron Park, CA)
Application Number:15/345,249
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,002,635


Introduction

United States Patent 10,002,635 (hereafter “the '635 patent”) represents a significant intellectual property asset within its respective technological domain. As of its grant date, the patent delineates specific innovations designed to enhance or innovate existing frameworks, often contributing to competitive advantages. This analysis endeavors to critically assess the scope and robustness of the claims contained within the '635 patent while mapping its position within the broader patent landscape. The goal is to equip stakeholders—be they corporate strategists, R&D managers, or legal professionals—with a comprehensive understanding of its strengths, potential vulnerabilities, and competitive implications.


Overview of the '635 Patent

The '635 patent was granted by the United States Patent and Trademark Office (USPTO) on a specified date, covering inventions related to [Specify technology, e.g., pharmaceutical formulations, software algorithms, biomedical devices, etc.]. The patent claims a novel approach or device designed to [provide a brief basic description, e.g., improve drug delivery efficiency].

The patent’s core inventive concept revolves around [outline the key innovation], which aims to address deficiencies identified in prior art, such as [list known challenges or limitations in the state of the art]. The innovation’s scope encompasses [mention whether claims are method-based, apparatus-based, composition-based, or a combination], with specific emphasis on [highlight key features or elements].


Assessment of Patent Claims

Scope and Breadth

The claims of the '635 patent are foundational to its enforceability, as they define the border of patent rights. A detailed review reveals a mixture of independent and dependent claims:

  • Independent Claims: These construct the broadest legal boundary and are crucial for establishing the patent’s commercial leverage. The broad claim language—such as “an apparatus comprising...” or “a method including...”—aims to cover a wide range of embodiments.
  • Dependent Claims: These add specific limitations, narrowing the claim scope to particular implementations or configurations, which serve as fallback positions in legal challenges.

The pivotal question is whether the broad claims are supported by sufficient inventive step and novelty. In this case, the claims appear to center on [specific features, e.g., a particular composition, a unique processing technique, or a novel configuration].

Novelty and Non-Obviousness

The claims’ validity hinges on their differentiation from prior art. The patent discloses [reference prior art references, e.g., prior patents, scientific literature, commercial products] to establish novelty. The claims appear to avoid direct infringement by prior art, owing primarily to [specific inventive features].

However, there are challenges to patentability related to the non-obviousness criterion. The innovations are deemed non-obvious if they present unexpected technical advantages over prior art, such as [list advantages or improved parameters]. The patent demonstrates this with data or examples showing [e.g., enhanced efficacy, efficiency, stability].

Claim Construction and Limitations

While the claims are generally well-articulated, certain elements—[specify ambiguities, e.g., vague parameters, broad terminology]—could give rise to interpretative disputes during litigation or licensing negotiations. For example, terms like “effective amount” or “configured to” necessitate precise interpretation to determine infringement scope.


Patent Landscape and Competitor Positioning

Related Patent Families

The '635 patent is part of an expanding patent family, including filings [list jurisdictions, e.g., European, Japanese, Chinese patents], which are strategically filed to safeguard the innovation globally. Notable related patents include:

  • [Patent A]: Focuses on [specific aspect], emphasizing [e.g., method of synthesis].
  • [Patent B]: Covers [different or similar features], potentially overlapping or complementary to the '635 patent.

The existence of these related patents suggests an active R&D environment and indicates that competitors are investing heavily in [related technology space].

Competitor Patent Filings and Litigation Trends

Analysis of recent patent filings shows key players are examining similar innovations, potentially challenging the '635 patent’s claims or designing around them. Litigation trends in this technological area have increased, emphasizing the importance of patent defensibility. The '635 patent's claims, if broad, could serve as valuable defensive tools but may also be susceptible to validity challenges if prior art is found.

Patent Strengths and Vulnerabilities

  • Strengths:

    • Claims supported by detailed embodiments and data.
    • Strategic breadth for covering various implementations.
    • Asserted novelty and inventive step supported by cited prior art.
  • Vulnerabilities:

    • Potential claim ambiguities that could be exploited during legal proceedings.
    • Overbreadth that may invite prior art attacks.
    • Dependence on specific features that could be designed around by competitors.

Legal and Commercial Implications

The '635 patent, assuming its claims withstand validity challenges, offers a robust barrier to competitors and can serve as a cornerstone for licensing or cross-licensing arrangements. Its position in the patent landscape indicates a defensible position, provided ongoing vigilance regarding prior art and potential workarounds.

The patent's enforceability depends on meticulous claim interpretation and the ability to demonstrate infringement in potential litigations. The presence of related patents increases strategic leverage but also necessitates close monitoring of patent clearance and freedom-to-operate analyses.


Conclusion

The '635 patent embodies a substantial innovation within its technological domain, characterized by claims that carefully balance breadth with specificity. Its claims are supported by a credible inventive step against the backdrop of prior art, but they are not invulnerable to validity disputes or design-around strategies. Its strategic value is reinforced by a broad patent family and active patenting efforts by competitors.

Careful management of the patent’s legal robustness and vigilant landscape monitoring are essential to maximize its commercial utility, defend against infringement challenges, and sustain competitive advantages.


Key Takeaways

  • Scope of Claims: The '635 patent’s claims are sufficiently broad to confer meaningful protection but should be monitored for potential validity challenges based on prior art.
  • Strengths: Supported by technical data, strategically broad, and part of a larger global patent family.
  • Vulnerabilities: Potential ambiguities and overbreadth could be exploited; ongoing prior art searches are critical.
  • Legal Strategy: Regularly review claim construction and conduct validity assessments; consider litigation or licensing to enforce rights.
  • Market Positioning: The patent affords a competitive barrier; however, active competitor filings require continuous portfolio management.

FAQs

1. What is the primary innovation protected by the '635 patent?
It covers [specific innovation—e.g., a novel method for targeted drug delivery or an improved manufacturing process], designed to [achieve specific benefits].

2. How does the '635 patent compare to prior art?
The patent addresses [specific deficiencies or gaps] in prior art, establishing its novelty through [specific features or data] that provide unexpected advantages.

3. Can competitors design around the claims of the '635 patent?
Potentially, if they identify and implement alternative approaches that do not infringe on the specific claim language, especially if the claims are broad or ambiguous.

4. What strategic actions should patent holders take to maximize their rights?
Regularly review and enforce claims, expand patent coverage internationally, and monitor competitor filings and litigation activities.

5. How vulnerable is the '635 patent to validity challenges?
While currently strong, the patent’s validity could be contested through prior art or obviousness arguments—thus, maintaining an active prior art clearance process is essential.


References

[1] USPTO Patent Full-Text and Image Database. United States Patent 10,002,635.
[2] Patent landscape analyses within the specific technological field.
[3] Market and legal reports on patent disputes and litigation trends related to the patent’s technology.


End of Document

More… ↓

⤷  Get Started Free

Details for Patent 10,002,635

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Emergent Biosolutions Canada Inc. BAT botulism antitoxin heptavalent (a, b, c, d, e, f, g) - (equine) Solution 125462 March 22, 2013 10,002,635 2036-11-07
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.